SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Denham JW. How do we bring an acceptable level of radiotherapy services to a dispersed population? Australas Radiol. 1995; 39: 171173.
  • 2
    Barton MB. Radiotherapy utilisation in New South Wales from 1996 to 1998. Australas Radiol. 2000; 44: 483484.
  • 3
    Lote K, Moller T, Nordman E, et al. Resources and productivity in radiation oncology in Denmark, Finland, Iceland, Norway and Sweden during 1987. Acta Oncol. 1991; 30: 555561.
  • 4
    Moller TR, Brorsson B, Ceberg J, et al. A prospective survey of radiotherapy practice 2001 in Sweden. Acta Oncol. 2003; 42: 387410.
  • 5
    Mackillop WJ, Groome PA, Zhang-Salomoms J, et al. Does a centralised radiotherapy system provide adequate access in care? J Clin Oncol. 1997; 15: 12611271.
  • 6
    Mackillop WJ, Dixon P, Zhou Y, et al. Variations in the management and outcome of non-small cell lung cancer in Ontario. Radiother Oncol. 1994; 32: 105115.
  • 7
    Delaney G, Barton B, Jacob S. Estimation of an optimal radiotherapy utilization rate for breast cancer: a review of the evidence. Cancer. 2003; 98: 19771986.
  • 8
    Foroudi F, Tyldesley S, Walker H, Mackillop WJ. An evidence-based estimate of appropriate radiotherapy utilization rate for breast cancer. Int J Radiat Oncol Biol Phys. 2002; 53: 12401253.
  • 9
    Delaney G, Barton M, Jacob S, Jalaludin B. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol. 2003; 4: 120128.
  • 10
    Tyldesley S, Boyd C, Shulze K, Walker H, Mackillop WJ. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys. 2001; 49: 973985.
  • 11
    Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for gastrointestinal cancer: a review of the evidence. Cancer. 2004; 101: 657670.
  • 12
    Foroudi F, Tyldesley S, Barbera L, Huang J, Mackillop WJ. An evidence-based estimate of the appropriate radiotherapy utilization rate for colorectal cancer. Int J Radiat Oncol Biol Phys. 2003; 56: 12951307.
  • 13
    Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for melanoma. a review of the evidence. Cancer. 2004; 100: 12931301.
  • 14
    Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecological cancer. Part I—malignancies of the cervix, ovary, vagina and vulva. Cancer. 2004; 101: 671681.
  • 15
    Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecological cancer. Part II—carcinoma of the endometrium. Cancer. 2004; 101: 682692.
  • 16
    Foroudi F, Tyldesley S, Barbera L, Huang J, Mackillop WJ. Evidence-based estimate of appropriate radiotherapy utilization rate for prostate cancer. Int J Radiat Oncol Biol Phys. 2003; 55: 5163.
  • 17
    National Cancer Institute. PDQ cancer information summaries: treatment of lip and oral cavity cancer. Available at URL:http://www.nci.nih.gov (accessed April 10, 2002).
  • 18
    National Cancer Institute. PDQ cancer information summaries: treatment of laryngeal cancer. Available at URL:http://www.nci.nih.gov (accessed April 10, 2002).
  • 19
    National Cancer Institute. PDQ cancer information summaries: treatment of oropharyngeal cancer. Available at URL:http://www.nci.nih.gov (accessed April 10, 2002).
  • 20
    National Cancer Institute. PDQ cancer information summaries: treatment of hypopharyngeal cancer. Available at URL:http://www.nci.nih.gov (accessed April 10, 2002).
  • 21
    National Cancer Institute. PDQ cancer information summaries: treatment of nasopharyngeal cancer. Available at URL:http://www.nci.nih.gov (accessed April 10, 2002).
  • 22
    National Cancer Institute. PDQ cancer information summaries: treatment of salivary gland cancer. Available at URL:http://www.nci.nih.gov (accessed April 10, 2002).
  • 23
    National Cancer Institute. PDQ cancer information summaries: treatment of paranasal sinus and nasal cavity cancer. Available at URL:http://www.nci.nih.gov (accessed April 10. 2002).
  • 24
    National Cancer Institute. PDQ cancer information summaries: treatment of metastatic squamous neck cancer with occult primary. Available at URL:http://www.nci.nih.gov (accessed May 2, 2002).
  • 25
    BC Cancer Agency. Cancer management guidelines: cancer of the oral cavity. Available at URL:http://www.bccancer.bc.ca (accessed April 17, 2002).
  • 26
    BC Cancer Agency. Cancer management guidelines: cancer of the lip. Available at URL:http://www.bccancer.bc.ca (accessed April 17, 2002).
  • 27
    BC Cancer Agency. Cancer management guidelines—carcinoma of the oropharynx. Available at URL:http://www.bccancer.bc.ca (accessed April 17, 2002).
  • 28
    BC Cancer Agency. Cancer management guidelines: carcinoma of the hypopharynx. Available at URL:http://www.bccancer.bc.ca (accessed April 17, 2002).
  • 29
    BC Cancer Agency. Cancer management guidelines: carcinoma of the nasopharynx. Available at URL:http://www.bccancer.bc.ca (accessed April 17, 2002).
  • 30
    BC Cancer Agency. Cancer management guidelines: cancer of the larynx. Available at URL:http://www.bccancer.bc.ca (accessed April 17, 2002).
  • 31
    BC Cancer Agency. Cancer management guidelines: cancer of the salivary glands. Available at URL:http://www.bccancer.bc.ca (accessed April 17, 2002).
  • 32
    BC Cancer Agency. Cancer management guidelines: unknown primary cancer. Available at URL:http://www.bccancer.bc.ca (accessed December 5, 2002).
  • 33
    National Comprehensive Cancer Network. Practice guidelines in oncology: head and neck cancers, 2001–version. Available at URL:http://www.nccn.org (accessed May 10, 2003).
  • 34
    National Comprehensive Cancer Network. NCCN practice guidelines for occult primary tumors. Oncology. 1998; 12: 226309.
  • 35
    British Association of Otorhinolaryngologists Head and Neck Surgeons. Effective head and neck cancer management. Consensus document, 1998. Available at URL:http://www.orl-baohns.org (accessed April 2, 2003).
  • 36
    European School of Oncology/START (State of the Art Oncology in Europe). Cancer of the oropharynx—treatment guidelines [monograph on line]. Available at URL:http://www.cancerworld.org [accessed April 17, 2002].
  • 37
    European School of Oncology/START (State of the Art Oncology in Europe). Major and minor salivary gland tumours—treatment guidelines [monograph on line]. Available at URL:http://www.cancerworld.org[accessed May 14, 2002].
  • 38
    European School of Oncology/START (State of the Art Oncology in Europe). Cancer of the larynx—treatment guidelines. Available at URL:http://www.cancerworld.org (accessed April 17, 2002).
  • 39
    National Health and Medical Research Council. Guide to the development, implementation and evaluation of clinical practice guidelines. Appendix B, 56. Canberra: National Health and Medical Research Council, 1998.
  • 40
    Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR). Cancer in Australia 1998, series 17, CAN 12. Canberra: AIHW, 2001.
  • 41
    Luke C, Chapman P, Priest K, Roder D. Use of radiotherapy in the primary treatment of cancer in South Australia. Australas Radiol. 2003; 47: 161167.
  • 42
    Jones KR, Lodge-Rigal D, Reddick RL, et al. Prognostic factors in the recurrence of Stage I and II squamous cell cancer of the oral cavity. Arch Otolaryngol Head Neck Surg. 1992; 118: 483485.
  • 43
    McGuirt WF, Johnson JT, Myers EN, Rothfield R, Wagner R. Floor of mouth carcinoma. The management of the clinically negative neck. Arch Otolaryngol Head Neck Surg. 1995; 121: 278282.
  • 44
    Zitsch RP, Park CW, Renner GJ, Rea JL. Outcome analysis for lip carcinoma. Otolaryngol Head Neck Surg. 1995; 113: 589596.
  • 45
    Rowe DE, Carroll RJ, Day CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992; 26: 976990.
  • 46
    Spitz MR, Fueger JJ, Goepfert H, Hong WK, Newell GR. Squamous cell carcinoma of the upper aerodigestive tract. A case comparison analysis. Cancer. 1988; 61: 203208.
  • 47
    Lee NK, Goepfert H, Wendt CD. Supraglottic laryngectomy for intermediate-stage cancer: U.T.M.D. Anderson Cancer Center experience with combined therapy. Laryngoscope. 1990; 100: 831836.
  • 48
    Hinerman RW, Mendenhall WM, Amdur RJ, Stringer SP, Villaret DB, Robbins KT. Carcinoma of the supraglottic larynx: treatment results with radiotherapy alone or with planned neck dissection. Head Neck. 2002; 24: 456467.
  • 49
    Orus C, Leon X, Vega M, Quer M. Initial treatment of the early stages (I,II) of supraglottic squamous cell carcinoma: partial laryngectomy versus radiotherapy. Eur Arch Oto Rhino Laryngol. 2000; 257: 512516.
  • 50
    Calearo C, Pastore A, Storchi OF, Polli G. Parotid gland carcinoma: analysis of prognostic factors. Ann Otol Rhinol Laryngol. 1998; 107: 969973.
  • 51
    Spiro RH, Armstrong J, Harrison L, et al. Carcinoma of major salivary glands. Arch Otolaryngol Head Neck Surg. 1989; 115: 316321.
  • 52
    O'Brien CJ, Soong SJ, Herrera GA, Urist MM, Maddox WA. Malignant salivary tumors—analysis of prognostic features and survival. Head Neck Surg. 1986; 9: 8292.
  • 53
    North CA, Lee DJ, Piantadosi S, Zahurak M, Johns ME. Carcinoma of the major salivary glands treated by surgery or surgery plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 1990; 18: 13191326.
  • 54
    Sinnathamby K, Peters LJ, Laidlaw C, Hughes PG. The occult head and neck primary: to treat or not to treat? Clin Oncol (R Coll Radiol). 1997; 9: 322329.
  • 55
    Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB. Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol. 2000; 55: 121129.
  • 56
    Nguyen C, Shenouda G, Black MJ, Vuong T, Donath D, Yassa M. Metastatic squamous cell carcinoma to cervical lymph nodes from unknown primary mucosal sites. Head Neck. 1994; 16: 5863.
  • 57
    Wolfensberger M, Zbaeren P, Dulguerov P, Muller W, Arnoux A, Schmid S. Surgical treatment of early oral carcinoma—results of a prospective controlled multicenter study. Head Neck. 2001; 23: 525530.
  • 58
    SA Cancer Registry. Epidemiology of cancer in South Australia. September, 2000 (cancer series no. 22). Adelaide: South Australian Cancer Registry, 2000.
  • 59
    Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1989; 95: 2S4S.
  • 60
    FlemingID, CooperJS, HensenDE, et al., editors. AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven, 1998.
  • 61
    Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349: 20912098.
  • 62
    The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. New Engl J Med. 1991; 324: 16851690.
  • 63
    Merlano M, Benasso M, Corvo R, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 1996; 88: 583589.
  • 64
    Adelstein DJ, Saxton JP, Lavertu P, et al. A Phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable Stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck. 1997; 19: 567575.
  • 65
    Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000; 18: 14581464.
  • 66
    Bachaud J, David J, Boussin G, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: preliminary report of a randomized trial. Int J Radiat Oncol Biol Phys. 1991; 20: 243246.
  • 67
    Merlano M, Corvo R, Margarino G, et al. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck: the final report of a randomized trial. Cancer. 1991; 67: 915921.
  • 68
    Browman GP, Cripps C, Hodson DI, et al. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol. 1994; 12: 26482653.
  • 69
    Adelstein DJ, Lavertu P, Saxton JP, et al. Mature results of a Phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with Stage III and IV squamous cell carcinoma of the head and neck. Cancer. 2000; 88: 876883.
  • 70
    Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000; 355: 949955.
  • 71
    Maulard C, Housset M, Brunel P, et al. Postoperative radiation therapy for cervical lymph node metastases from an occult squamous cell carcinoma. Laryngoscope. 1992; 102: 884890.
  • 72
    O'Mara W, Butler NN, Nemechek AJ. Carcinomas of unknown primary in the head and neck. J LA State Med Soc. 2001; 153: 341346.
  • 73
    National Cancer Institute (Cancer Statistics Branch). SEER*Stat version 5.0. Surveillance, Epidemiology and End Results cancer incidence public-use database, 1973–2000. Bethesda: United States Department of Health and Human Services, 2002.
  • 74
    Northern and Yorkshire Cancer Registry and Information Service (NYCRIS). Northern and Yorkshire Cancer Networks. A report on incidence and management for the main sites of cancer, 1999. Available at URL:http://www.nycris.org.uk (accessed November 25, 2003).
  • 75
    Statewide Services Development Branch. NSW radiotherapy management information system report 2000. NSW Health Department, 2001, Sydney, Australia.